advances in cholestatic liver diseases an issue o
unosuppressants: Used in autoimmune cholestatic conditions with variable success. Emerging Pharmacotherapies Norursodeoxycholic acid: Potential antifibrotic properties. Synthetic bile acids and receptor modulators: Targeting TGR5 and other pathways. Anti-inflammatory a
